FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024923044> ?p ?o ?g. }

• W2024923044 endingPage "3788" @default.
• W2024923044 startingPage "3774" @default.
• W2024923044 abstract "Cynomolgus macaques were immunized by either the intramuscular (i.m.) or intranasal (i.n.) route with a HIV-1 peptide-based immunogen (C4-V3 89.6P) alone, or formulated with novel adjuvants to evaluate the ability of the adjuvants to augment peptide-specific systemic and mucosal immune responses. A mutant cholera toxin, CT-E29H, or the combination of recombinant human IL-1α (rhIL-1α) protein and recombinant human GM-CSF (rhGM-CSF) protein were tested as adjuvants for i.n. immunization, while a stable emulsion of a synthetic monophosphoryl lipid A (MPL) analogue (RC529-SE) plus rhGM-CSF protein was tested as an adjuvant for i.m. immunization. Macaques immunized i.n. with peptide alone failed to elicit an anti-C4-V3 89.6P antibody response in serum. In contrast, all the tested peptide/adjuvant formulations elicited peptide-specific immune responses. RC529-SE/rhGM-CSF elicited the highest peak anti-peptide IgG geometric mean titer in serum (1:32,768 at week 25) followed by rhIL-1α/rhGM-CSF (1:1217 at week 10) and CT-E29H (1:256 at week 25). Measurable SHIV neutralizing antibody responses were detectable in only one macaque immunized i.m. with peptide formulated with RC529-SE/rhGM-CSF. Macaques immunized by the i.n. route with peptide in combination with CT-E29H failed to elicit measurable antibody responses at nasal or genital mucosal surfaces. In contrast, antibody responses at the nasal and genital mucosa were detected in macaques immunized by the i.n. route with peptide in combination with rhIL-1α/rhGM-CSF. However, antibody responses at the nasal and genital mucosa were highest in macaques immunized parenterally with peptide in combination with the adjuvants RC529-SE/rhGM-CSF. These results suggest that parenteral vaccine administration in combination with the appropriate adjuvant formulation can elicit vaccine-specific humoral immune responses in both systemic and mucosal compartments." @default.
• W2024923044 created "2016-06-24" @default.
• W2024923044 creator A5004036928 @default.
• W2024923044 creator A5007240363 @default.
• W2024923044 creator A5012554194 @default.
• W2024923044 creator A5032070701 @default.
• W2024923044 creator A5033703241 @default.
• W2024923044 creator A5047571769 @default.
• W2024923044 creator A5047863309 @default.
• W2024923044 creator A5051827275 @default.
• W2024923044 creator A5054579074 @default.
• W2024923044 creator A5056994923 @default.
• W2024923044 creator A5075537021 @default.
• W2024923044 creator A5085238122 @default.
• W2024923044 date "2004-09-01" @default.
• W2024923044 modified "2023-09-29" @default.
• W2024923044 title "A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques" @default.
• W2024923044 cites W1516411795 @default.
• W2024923044 cites W1520970133 @default.
• W2024923044 cites W1529615732 @default.
• W2024923044 cites W1530302667 @default.
• W2024923044 cites W1577158615 @default.
• W2024923044 cites W1579769974 @default.
• W2024923044 cites W1587830797 @default.
• W2024923044 cites W1597624310 @default.
• W2024923044 cites W1620676137 @default.
• W2024923044 cites W1975010250 @default.
• W2024923044 cites W1976816088 @default.
• W2024923044 cites W1977983409 @default.
• W2024923044 cites W1992942125 @default.
• W2024923044 cites W2006104205 @default.
• W2024923044 cites W2010527204 @default.
• W2024923044 cites W2010895610 @default.
• W2024923044 cites W2014065675 @default.
• W2024923044 cites W2020832650 @default.
• W2024923044 cites W2040353734 @default.
• W2024923044 cites W2040405441 @default.
• W2024923044 cites W2042183981 @default.
• W2024923044 cites W2057154810 @default.
• W2024923044 cites W2061535755 @default.
• W2024923044 cites W2069345108 @default.
• W2024923044 cites W2069469281 @default.
• W2024923044 cites W2081232373 @default.
• W2024923044 cites W2087420812 @default.
• W2024923044 cites W2094829985 @default.
• W2024923044 cites W2103826558 @default.
• W2024923044 cites W2105613110 @default.
• W2024923044 cites W2108838669 @default.
• W2024923044 cites W2118126822 @default.
• W2024923044 cites W2123825848 @default.
• W2024923044 cites W2131246210 @default.
• W2024923044 cites W2133538215 @default.
• W2024923044 cites W2135358682 @default.
• W2024923044 cites W2135720956 @default.
• W2024923044 cites W2135953287 @default.
• W2024923044 cites W2139425926 @default.
• W2024923044 cites W2139659516 @default.
• W2024923044 cites W2146482839 @default.
• W2024923044 cites W2147664127 @default.
• W2024923044 cites W2149849615 @default.
• W2024923044 cites W2151164451 @default.
• W2024923044 cites W2156474535 @default.
• W2024923044 cites W2161045200 @default.
• W2024923044 cites W2162143419 @default.
• W2024923044 cites W2164835119 @default.
• W2024923044 cites W2171387123 @default.
• W2024923044 cites W2256927828 @default.
• W2024923044 cites W2343722635 @default.
• W2024923044 cites W277141492 @default.
• W2024923044 cites W308058696 @default.
• W2024923044 cites W4232504682 @default.
• W2024923044 cites W4254743277 @default.
• W2024923044 doi "https://doi.org/10.1016/j.vaccine.2004.03.011" @default.
• W2024923044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15315859" @default.
• W2024923044 hasPublicationYear "2004" @default.
• W2024923044 type Work @default.
• W2024923044 sameAs 2024923044 @default.
• W2024923044 citedByCount "52" @default.
• W2024923044 countsByYear W20249230442012 @default.
• W2024923044 countsByYear W20249230442013 @default.
• W2024923044 countsByYear W20249230442014 @default.
• W2024923044 countsByYear W20249230442015 @default.
• W2024923044 countsByYear W20249230442016 @default.
• W2024923044 countsByYear W20249230442019 @default.
• W2024923044 countsByYear W20249230442020 @default.
• W2024923044 crossrefType "journal-article" @default.
• W2024923044 hasAuthorship W2024923044A5004036928 @default.
• W2024923044 hasAuthorship W2024923044A5007240363 @default.
• W2024923044 hasAuthorship W2024923044A5012554194 @default.
• W2024923044 hasAuthorship W2024923044A5032070701 @default.
• W2024923044 hasAuthorship W2024923044A5033703241 @default.
• W2024923044 hasAuthorship W2024923044A5047571769 @default.
• W2024923044 hasAuthorship W2024923044A5047863309 @default.
• W2024923044 hasAuthorship W2024923044A5051827275 @default.
• W2024923044 hasAuthorship W2024923044A5054579074 @default.
• W2024923044 hasAuthorship W2024923044A5056994923 @default.
• W2024923044 hasAuthorship W2024923044A5075537021 @default.
• W2024923044 hasAuthorship W2024923044A5085238122 @default.

• next